Wyss Geneva signs collaboration with Bio-Techne to advance 3D multiomics
The Wyss Center for Bio and Neuroengineering (Wyss Geneva) has signed a collaboration agreement with Bio-Techne Corporation to develop automated technology for simultaneous RNA and protein detection in three-dimensional tissue specimens. The initiative, carried out with Bio-Techne’s spatial biology brand Lunaphore, will enable high-resolution multiomic analysis in intact 3D samples.
By automating complex workflows, the partnership aims to accelerate drug discovery, improve diagnostics, and reduce reliance on animal testing through organoid models and predictive AI approaches. “3D multiomics will greatly enhance spatial insights gathering in the future, with the power to transform how we understand biology. Partnering with Bio-Techne is an extraordinary opportunity to turn that ambition into reality,” said Dr. Stéphane Pages, Director of Neuroimaging at Wyss Geneva.
This collaboration reflects Wyss Geneva’s mission to drive innovation in neuroengineering and translational research, expanding the possibilities of spatial biology and advancing ethical biomedical practices.
Advancing automated 3D multiomics technology and accelerating spatial biology
“This collaboration reflects Bio-Techne’s commitment to advancing spatial biology through meaningful partnerships and cutting-edge technology,” said Matt McManus, President of the Diagnostics and Spatial Biology Segment at Bio-Techne. “By combining our expertise in RNA and protein detection with Wyss Geneva’s leadership in 3D translational research, we are enabling new possibilities in preclinical modeling and accelerating the path from discovery to impact.”
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and has approximately 3,100 employees worldwide.